10-Q: Vicarious Surgical Reports Reduced Q1 2026 Losses Amid Cost Cuts

Vicarious Surgical Inc. reported a net loss of $7.3 million for the first quarter of 2026, a significant reduction from the prior year's $15.4 million loss, driven by substantial decreases in operating expenses.

Summary

• Vicarious Surgical Inc. reported a net loss of $7.3 million for the three months ended March 31, 2026, a decrease from $15.4 million in the same period of 2025.
• Total operating expenses were reduced by 52% to $7.5 million, primarily due to a 61% decrease in average headcount.
• The company's cash, cash equivalents, and short-term investments totaled $3.7 million as of March 31, 2026, which is not expected to be sufficient for the next twelve months, raising substantial doubt about its ability to continue as a going concern.
• The company expects its current cash reserves to be sufficient only through the second quarter of 2026.
• Trading of the company's Class A common stock was suspended by the NYSE on March 3, 2026, and subsequently moved to the OTCQB Venture Market.
• A reverse stock split was approved by stockholders on April 8, 2026, to potentially meet Nasdaq listing requirements.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to the substantial doubt about the company's going concern status, the NYSE delisting, and the move to a less liquid market, despite cost-cutting measures.

Positives

• Significant reduction in operating expenses by 52% to $7.5 million, driven by a 61% decrease in average headcount.
• Net loss decreased by 52% to $7.3 million for the quarter compared to $15.4 million in the prior year.
• The company successfully moved its Class A common stock listing from OTCID to the OTCQB Venture Market on March 24, 2026.
• Stockholders approved a reverse stock split on April 8, 2026, aimed at potentially listing on the Nasdaq Capital Market.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern, with current cash expected to last only through the second quarter of 2026.
• The NYSE suspended trading and initiated delisting proceedings for the Class A common stock on March 3, 2026.
• The company's Class A common stock is now quoted on the OTCQB Venture Market, which is a significantly more limited market than the NYSE, potentially leading to reduced liquidity and depressed trading prices.
• The company has not yet generated any revenue and does not expect to until FDA authorization is received.
• Material weaknesses in internal control over financial reporting were identified, including issues with segregation of duties, reconciliation, IT controls, and risk assessment.

Risks

• The company's ability to continue as a going concern is dependent on raising additional debt or equity capital, and there is no assurance that such capital will be available on acceptable terms.
• The delisting from the NYSE and quotation on the OTCQB could materially limit the number of investors, negatively impact the ability to raise equity financing, and reduce liquidity.
• Failure to obtain Nasdaq listing approval could result in continued trading on OTC markets, leading to reduced visibility, liquidity, and value of the Class A common stock.
• The company faces competition from companies with greater financial, technological, production, and marketing resources.
• The success, cost, and timing of product development and regulatory approval for the Vicarious Surgical System are uncertain.
• The company's ability to protect its intellectual property rights is critical and failure to do so could adversely affect its business.

Future Outlook

The company expects net losses to continue as it invests in product development and its clinical pathway. Current cash reserves are projected to be sufficient only through the second quarter of 2026, necessitating the pursuit of additional equity or debt financing. Future capital requirements will depend on clinical trial scope, market authorization timing, commercialization success, and other R&D and operational costs. The company has a new universal shelf registration statement allowing for up to $100 million in offerings.

Management Comments

• "We are combining advanced miniaturized robotics, computer science, sensing and 3D visualization to build a new category of intelligent and affordable single-port surgical robots that virtually transport surgeons inside the patient to perform minimally invasive surgery."
• "With our next-generation robotics technology, which is being designed with proprietary human-like motion, we are seeking to improve surgical precision, ergonomics, and procedural efficiency, with the goal of improving patient outcomes and the cost and efficacy of surgical procedures over time."
• "We estimate that there are 45 million soft tissue abdominal and gynecological surgical procedures performed annually worldwide that could potentially be addressed with the Vicarious Surgical System."
• "We expect that our cash, cash equivalents and short-term investments will be sufficient to support our operations through the second quarter of 2026."
• "As such, there is substantial doubt about the Companys ability to continue as a going concern."

Industry Context

StockSavvy.ai notes that Vicarious Surgical's focus on developing a new category of intelligent, affordable single-port surgical robots aligns with the broader trend in the medical device industry towards minimally invasive procedures and robotic-assisted surgery. However, the company's current financial precariousness, including its going concern status and delisting from the NYSE, highlights the significant capital demands and long development cycles inherent in this sector, where established players often have substantial R&D budgets and market access.

Comparison to Industry Standards

• Companies in the robotic surgery space, such as Intuitive Surgical, have achieved significant market penetration and revenue generation, demonstrating the potential for successful commercialization. However, these companies typically have much larger market capitalizations and established revenue streams.
• The significant reduction in operating expenses (52%) and headcount (61%) by Vicarious Surgical indicates a strong focus on cost preservation, which is a common strategy for early-stage medical device companies facing liquidity challenges, but it also suggests a scaled-back development or operational pace compared to more mature companies.
• The move to the OTCQB market is a common step for companies that do not meet the listing requirements of major exchanges like the NYSE or Nasdaq, but it generally results in lower trading volumes and less investor interest compared to companies listed on national exchanges.

Corporate Governance

Legal Proceedings

• As of the date of the report, the company is not party to any material pending legal proceedings.

Stakeholder Impact

• Shareholders: Potential dilution from future equity raises, reduced liquidity due to OTCQB listing, and uncertainty regarding Nasdaq listing. Stockholders approved a reverse stock split to potentially improve marketability.
• Employees: Impacted by a 61% reduction in average headcount, indicating significant workforce changes.
• Creditors: The company's going concern status and need for financing may impact its ability to meet future obligations.
• Investors: Reduced market access and liquidity due to NYSE delisting and OTCQB quotation.

Next Steps

• Continue to actively pursue additional equity or debt financing.
• Seek FDA authorization for the Vicarious Surgical System.
• Expand applications for the Vicarious Surgical System into other surgical procedures.
• Implement additional review controls and processes for internal control remediation.
• Potentially list Class A common stock on the Nasdaq Capital Market following a reverse stock split.

Key Dates

Recommendation

While the company has made progress in reducing expenses and has a potentially disruptive technology, the significant going concern issues, NYSE delisting, and move to OTC markets present substantial risks. The potential for a Nasdaq listing via a reverse stock split offers a path to improved liquidity and investor access, but this is not guaranteed. A 'hold' recommendation reflects the balance between the long-term technological potential and the immediate financial and market access challenges.

Keywords

Vicarious Surgical, Form 10-Q, Quarterly Report, Surgical Robot, Medical Device, Biotechnology, Financial Results, Net Loss, Operating Expenses, Going Concern, NYSE Delisting, OTCQB, Nasdaq Listing, Reverse Stock Split, FDA Authorization